Investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket

|About: Dynavax Technologies C... (DVAX)|By:, SA News Editor

Merck's announcement of positive Phase 3 results for KEYTRUDA (pembrolizumab) in late-stage melanoma has stoked modest premarket buying in Dynavax Technologies (NASDAQ:DVAX). Shares are up 14% on light volume.

Tomorrow, April 17, data from a Phase 1b study assessing the combination of lead candidate SD-101 and pembrolizumab in advanced melanoma will be presented.

Previously: Merck's Keytruda shows treatment benefit in late-stage study in advanced melanoma; shares up 1% premarket (April 16)

Previously: Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours (June 2, 2017)

Subscribe for full text news in your inbox